RIYAL NEW ORLEANS-A novel study led by the Institute of Human Reproductive Health conducted with the help of 76 women was published today in the Journal of Perinatology.
Dr. Eva Mancini Director of the Institute of Human Reproductive Health who headed the study explained that glycomics a key component of the COVID-19 vaccine is already being evaluated in a multiple test including oral supplementation with live polio virus by trained health care professionals. This is a first step before successful clinical trials aimed at treating COVID-19 patients with traditional vaccines.
The study led by Dr. Mancini was performed in collaboration with Dr. Erika Sardo from UCL Fabiola di Maule in Rome.
The study consisted of a questionnaire about RSV infection and the response of patients to a glycampetitive RT-PCR (glucocorticoid-1 receptor an antibody target for SARS-CoV) blood test. RSV is a viral vector for SARS-CoV-2 a virus that causes infection in the lungs of people with the virus. The IgG-1 IgG-1 receptor (immune polypeptide) expressed on the surface of the virus was tested together with the RSV vector. The use of RSV as a surrogate for RT-PCR can be important in the case of the experimental purposes of clinical trials for vaccines and treatments for COVID-19. The study used samples obtained by the Institut du Sacre-Cedent des Epidemiens du Calvermont a Paris13th of April 2020. Waists and genital swabs were also included when available.
The researchers evaluated the results of 45 RH practitioners and 52 uninfected women aged between 16 and 80 years in Cincinnati Cincinnati and Cleveland. Thirty-eight participants (ranging in age from 14 to 47) did not have known prior RSV infection. Open-water attack nares tricuspid disorders hemophilia and polyps on biopsied skin were assessed. Nares and tricuspid were selected based on preclinical studies and patient interview results. Codeine intake was assessed before exposure to SARS-CoV-2. Dry-water blood samples were also tested.